ArticleThe Journal of antibiotics2025
New oligomycin derivatives inhibit anchorage-independent growth of pancreatic cancer cells.
Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) play a crucial role in cancer progression, recurrence, and therapy resistance through their abilities to self-renew, differentiate, and evade treatment. Disrupting the interaction between CSCs and their tumor microenvironment, especially cancer-associated fibroblasts (CAFs), represents a promising therapeutic strategy. We screened microbial metabolites to identify compounds that specifically inhibit anchorage-independent (3D) growth, a key characteristic of CSCs, in the presence of CAF-conditioned medium (CAF-CM). Two new oligomycin analogs, oligomycins EX-1 (1) and 2 (2), were successfully isolated from Nocardia sp. MK165-SF8. Structural analysis using NMR and MS techniques revealed their distinctive chemical characteristics, particularly the presence of an exomethylene group. In biological assays, 1 and 2 demonstrated potent inhibitory activity against mitochondrial complex V, comparable to oligomycin A. Additionally, they showed enhanced effectiveness in suppressing both 3D growth and the expression of CD44 variants in pancreatic cancer cells cultured in CAF-CM.
Indexed as
Identifiers
40456946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.